Immune responses provide clues for HIV vaccine development

21 octubre 2015

Recent research has yielded new information about immune responses associated with — and potentially responsible for — protection from HIV infection, providing leads for new strategies to develop an HIV vaccine. Results from the RV144 trial, reported in 2009, provided the first signal of HIV vaccine efficacy: a 31 percent reduction in HIV infection among vaccinees. Since then, an international research consortium has been searching for molecular clues to explain why the vaccine showed this modest protective effect.